Changes in life expectancy for cancer patients over time since diagnosis

Botta, Laura; Maso, Luigino Dal; Guzzinati, Stefano; Panato, Chiara; Gatta, Gemma; Trama, Annalisa; Tagliabue, Giovanna; Casella, Claudia; Caruso, Bianca; Michiara, Maria; Ferretti, Stefano; Sensi, Flavio; Tumino, Rosario; Toffolutti, Federica; Russo, Antonio; Caiazzo, Anna Luisa; Mangone, Lucìa; Mazzucco, Walter; Iacovacci, Silvia; Ricci, Paolo; Gola, G; Candela, Giuseppa; Sardo, Antonella Sutera; Angelis, Roberta De; Buzzoni, Carlotta; Capocaccia, Riccardo

doi:10.1016/j.jare.2019.07.002

Cited by 27 publications

(23 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most reported new cases involve the lung and breast, with colorectal cancer third, prostate cancer fourth, and stomach cancer fifth ( 1 , 2 ). Each reported cancer is associated with variable overall life expectancies, years of life lost, and 5-year survival rate ( 3 – 6 ).…”

Section: Introductionmentioning

confidence: 99%

C-Reactive Protein and Cancer—Diagnostic and Therapeutic Insights

et al. 2020

View full text Add to dashboard Cite

Cancer disease describes any pathology involving uncontrolled cell growth. As cells duplicate, they can remain localized in defined tissues, forming tumor masses and altering their microenvironmental niche, or they can disseminate throughout the body in a metastatic process affecting multiple tissues and organs. As tumors grow and metastasize, they affect normal tissue integrity and homeostasis which signals the body to trigger the acute phase inflammatory response. C-reactive protein (CRP) is a predominant protein of the acute phase response; its blood levels have long been used as a minimally invasive index of any ongoing inflammatory response, including that occurring in cancer. Its diagnostic significance in assessing disease progression or remission, however, remains undefined. By considering the recent understanding that CRP exists in multiple isoforms with distinct biological activities, a unified model is advanced that describes the relevance of CRP as a mediator of host defense responses in cancer. CRP in its monomeric, modified isoform (mCRP) modulates inflammatory responses by inserting into activated cell membranes and stimulating platelet and leukocyte responses associated with acute phase responses to tumor growth. It also binds components of the extracellular matrix in involved tissues. Conversely, CRP in its pentameric isoform (pCRP), which is the form quantified in diagnostic measurements of CRP, is notably less bioactive with weak anti-inflammatory bioactivity. Its accumulation in blood is associated with a continuous, low-level inflammatory response and is indicative of unresolved and advancing disease, as occurs in cancer. Herein, a novel interpretation of the diagnostic utility of CRP is presented accounting for the unique properties of the CRP isoforms in the context of the developing pro-metastatic tumor microenvironment.

show abstract

Section: Introductionmentioning

confidence: 99%

C-Reactive Protein and Cancer—Diagnostic and Therapeutic Insights

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Complete data were available for the remaining 127 patients. The incidence obtained was compared with those recently reported from Campania region (AIRTum data) [50].…”

Section: Methodsmentioning

confidence: 99%

Post-Transplant Lymphoproliferative Diseases in an Elderly Population Who Underwent Cardiac Transplantation: Role of Physical Activity Rehabilitation Program

Sica¹,

Sagnelli²,

Fasano³

et al. 2019

Preprint

View full text Add to dashboard Cite

The incidence of post transplantation lymphoproliferative disorders (PTLDs) and other neoplasms in organ transplant patients is higher than in the non-transplanted population. This event is more frequent in older subjects, due, at least in part, to the immune dysfunction induced by immunosuppressants administered to prevent rejection. Alterations of the immune system mechanisms of protection against carcinogenesis appear to be the key role in the in the pathogenesis of these neoplasms.The data of our study on the incidence of neoplasms occurred during a long-term follow-up in an elderly population after they underwent cardiac transplantation. This study gives, also evidence of the favorable effect of physical activity programs on cardiorespiratory and psychomotor function.

show abstract

“…It has been found that patients who survive for 4 years following diagnosis are living longer, to the point that their life expectancy is approaching that of the general population. With increasing periods of survival since diagnosis, particularly for more lethal cancers, patients’ life expectancy tends to increase during the first three to 5 years immediately after diagnosis [ 24 , 25 ]. In Israel, the National Cancer Registry reported that relative five-year survival 2 of invasive cancer has increased significantly, based on a comparison between those diagnosed during 1996–2000 and those diagnosed during 2007–2011.…”

Section: The Insurability Of Innovative Pharmaceutical Cancer Technolmentioning

confidence: 99%

The insurability of innovative pharmaceutical cancer technologies

Greenberg

Dotan

Arazi

2020

Isr J Health Policy Res

View full text Add to dashboard Cite

The scientific literature, including several papers published in the IJHPR, has raised the issue of the spiraling cost of cancer treatment, including that of cancer drugs and other technologies such as gene and cell therapies. In this perspective, we review three criteria for insurability and show that they may not be met.First, the uncertain trends in the cost of innovative pharmaceutical and other cancer technologies make the maximum possible loss per event very difficult to predict and to manage in terms of insurer solvency. Second, the uncertainty of the price, the period that a drug or other cancer care technology will be administered and the number of individuals that will need the technology makes it difficult to predict future insurance premiums and whether they will be affordable to the target population. Third, public coverage needs to be consistent with societal values. However, pressure to limit public coverage will gradually increase as the possibilities of innovative pharmaceutical cancer technologies expand, thus transferring the burden onto commercial insurance. This is a phenomenon that is virtually impossible to predict accurately, but which will certainly undermine the status of health as a social good.We conclude that the financial risk arising from the use of innovative pharmaceutical cancer technologies fails to meet the aforementioned criteria, thus raising questions as to the sustainability of commercial insurance for cancer treatment and suggesting the need for the state to take greater responsibility for covering this financial risk in the future.

show abstract

Changes in life expectancy for cancer patients over time since diagnosis

Cited by 27 publications

References 21 publications

C-Reactive Protein and Cancer—Diagnostic and Therapeutic Insights

C-Reactive Protein and Cancer—Diagnostic and Therapeutic Insights

Post-Transplant Lymphoproliferative Diseases in an Elderly Population Who Underwent Cardiac Transplantation: Role of Physical Activity Rehabilitation Program

The insurability of innovative pharmaceutical cancer technologies

Contact Info

Product

Resources

About